Nirsevimab Drug Quiz

29 Questions

What is the mechanism of action of Nirsevimab?

Binds F protein on respiratory syncytial virus (RSV) to prevent fusion

What is the primary indication for using Nirsevimab?

RSV prevention for all infants and neonates in their first RSV season

What is a key unmet need that Nirsevimab aims to address?

Cost and convenience of treatment

What are the key adverse events associated with Nirsevimab?

Injection site reactions, upper respiratory tract infections

What is the reimbursement status of Nirsevimab according to CADTH?

Cannot determine cost, de novo evaluation is needed

What distinguishes Nirsevimab from Palivizumab as a competitor?

Shorter half-life and more frequent injections.

What is the line of therapy for Nirsevimab?

First-line for prevention of RSV

What distinguishes Abrysvo from Nirsevimab?

Shorter half-life and more frequent injections.

What distinguishes MK-1654 from Palivizumab and Nirsevimab?

Intravenous administration and faster onset of action.

What distinguishes RSV prevention with Nirsevimab from other treatments?

Only requires one intramuscular injection per RSV season.

What is the mechanism of action of Zoryve?

Inhibits PDE-4, leading to cAMP accumulation and activation of PKA signaling pathway

What is the primary indication for Zoryve?

Plaque Psoriasis

What distinguishes Zoryve from its competitors?

It is the first in its class and steroid-free

What is the market opportunity for Zoryve in terms of disease state?

Common - affects 125 million people worldwide

What is the line of therapy for Zoryve?

First line (and only) treatment for genitals and skin folds (intertriginous)

What are the key adverse events associated with Zoryve?

Hypersensitivity and topical redness/sensitivity

What is the reimbursement status of Zoryve according to CADTH?

CADTH recommends public plan reimbursement but not yet on provincial formularies

What is the unmet need that Zoryve aims to address?

No definitive care available for intertriginous psoriasis (skin folds)

What are the dosing considerations for Zoryve?

0.5mg/day for altered as patients become refractory/relapse treatment

What is the mechanism of action of Camzyos?

It is a reversible inhibitor of cardiac myosin ATPase, reducing actin-myosin cross-bridges to help reduce heart contractility.

What is the market opportunity for Empaveli?

It lies in treating a rare disease.

What is the key adverse event associated with Carvykti?

Cytokine storm

What is the line of therapy for Imcivree?

First-line therapy for genetic obesity.

Which company manufactures Carvykti?

Janssen/Legend BioTech

What is the reimbursement status for Empaveli?

Recommended reimbursement by public plan if insufficient response or intolerable to C5 inhibitor.

What is the dose and dosing considerations for Camzyos?

Oral self-administered medication taken once daily.

What is the unmet need addressed by Carvykti?

Rare disease with no current therapies targeting the underlying pathology.

What is the indication for Imcivree?

Market opportunity lies in treating a rare disease.

What is the mechanism of action of Empaveli?

It targets and inhibits the terminal complement C5 of the complement cascade.

Study Notes

Camzyos:Manufactured by Bristol-Myers-Squibb, used to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition where the left ventricle wall thickens and stiffens, obstructing blood flow out of the aorta. The only therapy targeting the underlying pathophysiology of HCM.
Mechanism of Action: A reversible inhibitor of cardiac myosin ATPase, reducing actin-myosin cross-bridges to help reduce heart contractility. Indicated for adults with NYHA stage 2 to 3 heart-failure and on BB or non-DHP CCB.
Market Opportunity: Rare disease affecting at least 1 in every 500 individuals.
Administration: Oral self-administered medication.
Line of Therapy: Second-line therapy after BB or non-DHP CCB.
Key Adverse Events: Induce heart failure due to systolic dysfunction.
Reimbursement Status: CADTH has recommended reimbursement under certain conditions and currently under negotiation with pCPA.
Carvykti:Manufactured by Janssen/Legend BioTech, used to treat multiple myeloma patients who have received at least three prior lines of therapy and are refractory to their last treatment.
Market Opportunity: Rare disease with no current therapies targeting the underlying pathology.
Administration: Must be administered within a designated CAR-T site (hospital).
Competitors: Abecma, Tecvayli, XPOVIO, and Blenrep.
Unmet Need: Incurable disease with low survival and poor health-related QoL.
Dose and Dosing Considerations: Single infusion.
Key Adverse Events: High risk of cytokine storm, immune effector-cell associated neurotoxicity syndrome, anemia, neutropenia, thrombocytopenia.
Reimbursement Status: CADTH has recommended reimbursement under certain conditions and currently under negotiation with pCPA.
Empaveli:Manufactured by Apellis Pharmaceuticals, used to treat paroxysmal nocturnal hemoglobinuria (PNH).
Mechanism of Action: Prevents C3 from splitting into C3a and C3b, impacting the complement activation cascade downstream and stopping both intravascular and extravascular hemolysis.
Indication: Market opportunity lies in treating a rare disease.
Administration: Self-administered subcutaneous infusion.
Line of Therapy: Second-line therapy after failing C5 inhibitor.
Competitors: Solaris and Ultomiris.
Unmet Need: Only treatment that addresses both intravascular and extravascular hemolysis.
Dose and Dosing Considerations: Dosed twice weekly.
Reimbursement Status: Recommended reimbursement by public plan if insufficient response or intolerable to C5 inhibitor.
Imcivree:Manufactured by Rhythm Pharmaceuticals, used to treat Bardet-Biedl Syndrome (BBS) and other genetic obesity in adults and adolescents 6 years and older.
Mechanism of Action: MC4R agonist, which reduces hunger, satiety, and decreased food intake, and weight loss.
Indication: Market opportunity lies in treating a rare disease.
Administration: Subcutaneous daily dosing at home.
Line of Therapy: First-line therapy for genetic obesity.
Competitors: Also MC4R agonist, but not for genetic obesity, and only symptomatically help with reducing appetite or weight loss.
Unmet Need: Rare disease with limited treatment options.
Reimbursement Status: Yet to be determined by regulatory agencies.
New Competitors: LB54640 in development.

Test your knowledge about the drug Nirsevimab, its manufacturer, mechanism of action, indication, and market opportunity. Learn about its use in preventing respiratory syncytial virus (RSV) in infants and neonates.

Make Your Own Quizzes and Flashcards

Convert your notes into interactive study material.